Market Overview

Mucopolysaccharidosis Disorders Drug Development Pipeline Review 2018 Featuring ArmaGen, Sangamo and AngioChem - ResearchAndMarkets.com

Share:

The "Mucopolysaccharidosis
Disorders Drug Development Pipeline Review, 2018"
report has
been added to ResearchAndMarkets.com's offering.

"Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018"
provides an overview of the pipeline landscape for mucopolysaccharidosis
disorders, a group of inherited lysosomal storage disorders.

It provides comprehensive information on the therapeutics under
development and key players involved in therapeutic development for
mucopolysaccharidosis I (MPS I) (Hurler syndrome), mucopolysaccharidosis
II (MPS II) (Hunter syndrome) and mucopolysaccharidosis III (MPS III)
(Sanfilippo syndrome), and features dormant and discontinued products.

Companies operating in the mucopolysaccharidosis disorders pipeline
space include ArmaGen, Sangamo and AngioChem.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage
    of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within
    this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to
    have happened in this disease area?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

  • Abeona Therapeutics Inc
  • AngioChem Inc
  • ArmaGen Inc
  • Axcentua Pharmaceuticals AB
  • BioMarin Pharmaceutical Inc
  • CRISPR Therapeutics
  • Denali Therapeutics Inc
  • Eloxx Pharmaceuticals Inc
  • GC Pharma
  • Immusoft Corp
  • JCR Pharmaceuticals Co Ltd
  • Laboratorios Del Dr Esteve SA
  • Lysogene SAS
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome)
  • OPKO Health Inc
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • Swedish Orphan Biovitrum AB

For more information about this report visit https://www.researchandmarkets.com/research/rl7npv/mucopolysaccharido?w=4

View Comments and Join the Discussion!